Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers December 15, 2018
Pharmacy Choice - News - Over-the-Counter Drugs - December 15, 2018

Pharmacy News

 Over-the-Counter Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 21 of 21     Go To Page:

12/14/18 - Innovus Pharma Announces All Cash Acquisition of All of the Assets of SupplementHunt.com, an E-Commerce Store with its Proprietary Sales Platform and Marketing Technology
Innovus Pharmaceuticals, Inc., an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men s and women's health and respiratory diseases, today announced the acquisition for cash of all of the assets of SupplementHunt.com, an E-Commerce...
12/14/18 - Janssen Signs Results-Based Contract With Oklahoma Health Care Authority for Its Long-Acting Injectable Schizophrenia Medicines
Janssen Pharmaceutical Companies, a subsidiary of Johnson and Johnson, issued the following news release:. The Janssen Pharmaceutical Companies of Johnson& Johnson announced today a results-based contract for long-acting injectable schizophrenia medicines with the Oklahoma Health Care Authority, which manages Oklahoma's Medicaid plan, SoonerCare.
12/14/18 - Janssen Submits Supplemental New Drug Application (sNDA) to FDA for XARELTO (rivaroxaban) to Prevent Venous Thromboembolism (VTE) in Acute Medically Ill Patients
The Janssen Pharmaceutical Companies of Johnson& Johnson announced today the submission of a supplemental New Drug Application for XARELTO to the U.S. Food and Drug Administration for the prevention of venous thromboembolism, or blood clots, in medically ill patients. "Despite being at high risk of VTE for up to six weeks when leaving the hos
12/13/18 - A Phase 1, Safety, Tolerability, and Distribution Study of a Microdose of Radiolabeled BIIB067 Co-administered With BIIB067 to Healthy Adults
By a News Reporter-Staff News Editor at Clinical Trials Week Staff editors report on the newly launched clinical trial, NCT03764488, which has the following summary description: "This study will assess the safety and tolerability of 99 mTc-MAG3-BIIB067 co-administered with unlabeled BIIB067 to healthy participants and will also evaluate the...
12/13/18 - Bausch Health Enters Into Definitive 'Stalking Horse' Agreement To Acquire Substantially All The Assets Of Synergy Pharmaceuticals Inc.
LAVAL- Bausch Health Companies Inc. announced today that it has entered into a definitive agreement to acquire certain assets of Synergy Pharmaceuticals Inc. in a transaction valued at approximately $200 million plus certain assumed liabilities. Under the terms of the agreement, and subject to Bankruptcy Court approval, Bausch Health will serve as
12/13/18 - Janssen Signs Results-Based Contract with Oklahoma Health Care Authority (OHCA) for its Long-Acting Injectable Schizophrenia Medicines
The Janssen Pharmaceutical Companies of Johnson& Johnson announced today a results-based contract for long-acting injectable schizophrenia medicines with the Oklahoma Health Care Authority, which manages Oklahoma's Medicaid plan, SoonerCare. The agreement was made between Janssen Pharmaceuticals, Inc. and OHCA. "Oklahoma is excited to work with
12/13/18 - Virtus Announces FDA Approval of its AB Rated Generic Levorphanol Tartrate 2mg Tablets CII
Virtus Pharmaceuticals, LLC, a specialty pharmaceutical company, today announced it has received an AB therapeutic equivalent rating and final U.S. Food and Drug Administration approval on its Abbreviated New Drug Application for a generic version of Levorphanol Tartrate 2 mg immediate release tablets. The company is preparing for launch to the mar
12/12/18 - Authorized Generic for EVZIO (naloxone HCl injection) to be Available at a Reduced List Price of $178
Kalo, a privately-held pharmaceutical company, today announced that it will offer an authorized generic of its EVZIO take home naloxone product at a list price of $178 per carton. Offered through kalo subsidiary IJ Therapeutics, the authorized generic will be made available in midyear 2019 well in advance of EVZIO's patent expirations.
12/12/18 - Dr. Reddy's announces the launch of over-the-counter store brand equivalent of Prilosec OTC Tablets, 20 mg in the U.S. Market
Hyderabad- Dr. Reddy's Laboratories Ltd. announced today the launch of Omeprazole Delayed-Release Tablets, 20 mg, an over-the-counter store-brand equivalent of Prilosec OTC Tablets, 20 mg, in the United States market as approved by the U.S. Food and Drug Administration. 'This launch illustrates our continued commitment to the OTC business as well a
12/12/18 - Global Dermatological Products Market to Experience Significant Growth during the Forecast Period 20 [ClickPress (UK)]
Biologic agents or protein-based drugs are increasingly used in dermatology for treatment of psoriasis. These products have also gained traction in the treatment of other inflammatory skin diseases. Based on the regulatory approach of biosimilars, increasing number of biosimilar drugs are set to enter Europe and the US in the coming years.
12/12/18 - New Phase 3 data demonstrate superiority of TREMFYA (guselkumab) vs Cosentyx (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 48
The Janssen Pharmaceutical Companies of Johnson& Johnson today announced results from the ECLIPSE study demonstrating that TREMFYA was superior to Cosentyx * in treating adults with moderate to severe plaque psoriasis for the primary endpoint assessed at week 48. Data from the multi-center, randomized, double-blind head-to-head Phase 3 study
12/12/18 - World Market for Precision Cancer Diagnostic Tests, 2018-2023
The "World Market for Precision Cancer Diagnostic Tests" report has been added to ResearchAndMarkets.com' s offering. World Market for Precision Cancer Diagnostic Tests, a market-based and industry-focused report, examines the global market environment for precision cancer testing products and procedures, including the following data:.
12/11/18 - Branded Generics Market to Expand at a Value CAGR of 7.3% by 2026: Branded Generics Market: Anti-Hypertensive Drugs Will Witness Significant Demand
Valley Cottage, NY 12/11/2018 Differential and innovative product strategies that are adopted by various multinational pharma companies have been fuelling the growth of branded generics market at a global scale. These strategies include establishing sustained local capabilities with the strong local talents, engaging in portfolio marketing,..
12/11/18 - Dr. Reddy's announces the launch of over-the-counter store brand equivalent of Prilosec OTC (Omeprazole Delayed-Release) Tablets, 20 mg in the U.S. Market
HYDERABAD, India& PRINCETON, N.J. Dr. Reddy s Laboratories Ltd. announced today the launch of Omeprazole Delayed-Release Tablets, 20 mg, an over-the-counter store-brand equivalent of Prilosec OTC Tablets, 20 mg, in the United States market as approved by the U.S. Food and Drug Administration. The combined market of Prilosec OTC and pri
12/11/18 - Global ePharmacy Market by Growth, Size, Supply, Demand, Comparative Analysis, Competitive market share forecast 2018-2025
Electronic pharmacy or internet pharmacy, commonly called as ePharmacy, is a method of enabling the online purchase of medicines. It offers the convenience to its customers in purchasing and delivering products, providing valuable information on the ...
12/11/18 - Innovus Pharma Announces Initiation of a Clinical Study to Evaluate the Tolerance and the Effect of Musclin on Muscle Health in Adults in the United States [Sport360]
Innovus Pharmaceuticals, Inc., an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve mens and women`s health and respiratory diseases, today announced the enrollment of the first participant in the clinical study to evaluate the effect and...
12/11/18 - Pharmaceutical Waste Management Market Emerging Trends, Global Opportunities, Current Trends and Latest Advancements with Key Companies Review
Pune, India 12/11/2018 Global Pharmaceutical Waste Management Market over the forthcoming years. Pharmaceutical wastes contain active ingredients which are known to cause harm to the environment and public health. Global Pharmaceutical Waste Management Market is marked by the presence of players such as Stericycle, Covanta Holding Corporation
12/10/18 - Innovus Pharma Announces Initiation of a Clinical Study to Evaluate the Tolerance and the Effect of Musclin? on Muscle Health in Adults in the United States
Innovus Pharmaceuticals, Inc., an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men s and women's health and respiratory diseases, today announced the enrollment of the first participant in the clinical study to evaluate the effect and
12/10/18 - Novartis data demonstrates consistent efficacy and tolerability of Kisqali combination therapy in HR+/HER2- advanced breast cancer
Basel- Novartis today announced data from subgroup analyses of the three pivotal Phase III MONALEESA trials showing that Kisqali plus endocrine therapy extended progression-free survival compared to endocrine therapy alone, regardless of the presence of visceral metastases in pre-, peri- and postmenopausal women with hormone receptor positive, huma
12/10/18 - Novartis Data Demonstrates Consistent Efficacy and Tolerability of Kisqali Combination Therapy in HR+/HER2- Advanced Breast Cancer in Patients With Difficult-to-Treat Visceral Disease
Novartis issued the following news release:. -Subgroup analyses of three pivotal Phase III MONALEESA trials showed Kisqali plus endocrine therapy extended PFS in all patients with and without visceral involvement compared to endocrine therapy alone; consistent with the overall study populations. "Nearly 60 percent of patients enrolled in the MONAL
12/8/18 - Novartis data demonstrates consistent efficacy and tolerability of Kisqali combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease
Novartis today announced data from subgroup analyses of the three pivotal Phase III MONALEESA trials showing that Kisqali plus endocrine therapy extended progression-free survival compared to endocrine therapy alone, regardless of the presence of visceral metastases in pre-, peri- and postmenopausal women with hormone receptor positive, human.
Articles(s): 1 - 21 of 21     Go To Page:


© 2018 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415